Recent Finacing
Recent Raise
Hemispherian, based in Oslo, develops GLIX small-molecule TET2 activators that trigger DNA damage response to induce cancer cell death; GLIX1 targets glioblastoma and GLIX5 targets platinum-resistant ovarian cancer.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
